MoneyWorks4Me

Glenmark Pharmaceuticals inform about media release

11 Apr 2022 Evaluate

Glenmark Pharmaceuticals has attached a media release today titled ‘Glenmark Specialty S.A. receives approval for conducting Phase 1 Clinical Trial of its Novel Molecule GRC 54276 in patients with Advanced Solid Tumors and Hodgkin’s Lymphoma’. 

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1783.25
Dr. Reddys Labs. 1202.40
Cipla 1329.50
Lupin 2007.10
Zydus Lifesciences 1154.00
View more..